UNSPSC 51433907: Nisoldipine

This classification denotes a calcium channel blocker with the molecular formula C20H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4I8HAB65SZ, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester but generally known as nisoldipine, which bears US NIH Compound Identifier 4499. European Medicines Agency schedules Nisoldipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09307MIG.

UNSPSC 51433907 Nisoldipine is a Commodity code representing a specific pharmaceutical ingredient used in emergency medical settings and managed healthcare programs. State and local governments procure nisoldipine and related branded or generic cardiovascular medications as part of Advanced Life Support medication supplies for fire rescue services, emergency medical transport, and pharmacy benefit programs serving public employees and Medicaid populations. Issuing bodies include city purchasing departments acquiring medications for fire rescue operations, state health and human services agencies managing pharmacy benefits for employee and beneficiary populations, and multistate cooperative purchasing alliances coordinating pharmaceutical procurement across member states and local government entities. The procurement typically involves either sealed-bid competitions for specific medication line items with firm fixed pricing and standardized delivery terms, or broader RFP and RFI mechanisms through which state agencies and purchasing cooperatives gather vendor capabilities and pricing for generic multi-source pharmaceuticals distributed through authorized wholesaler networks.

Recent activity appears concentrated in Texas and Minnesota, with secondary activity in Florida. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, seeking sealed bids for four specific medication line items including nisoldipine-adjacent products (Diltiazem, Labetalol, Epinephrine, and Adenosine) with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a one-year term plus two optional renewals; the solicitation carried a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response date, seeking generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements, reflecting preliminary market research rather than a formal competitive solicitation.